Quince Therapeutics Inc.
13F holders, Q3 2025 (September 30)At the end of Q3 2025, 45 institutions reported holding Quince Therapeutics Inc. in their 13F filings, up 4 from Q2 2025. 8 opened new positions and 4 sold out. The largest holders were Nantahala Capital Management, LLC ($5.0M), Vanguard Group Inc. ($2.9M) and Millennium Management ($2.3M). 3 famous investors held it, including Israel Englander (0.0% of Millennium Management's portfolio), Jim Simons / Peter Brown (0.0% of Renaissance Technologies's portfolio) and Ken Griffin (0.0% of Citadel Advisors's portfolio).
- Company
- Quince Therapeutics Inc.
- CUSIP
- 22053A107
- Latest filing quarter
- Q1 2026
History
Number of 13F holders
Total Exit/New Position Q2 2025 → Q3 2025
| Institutions | Total Value | |
|---|---|---|
| New Positions | 8 | $1.5M |
| Exits | 4 | $425K |
All 13F filers, Q2 2025 → Q3 2025: 4,572,825 shares bought and 358,972 shares sold, net +4,213,853 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 45 holders
| Nantahala Capital Management, LLC | 0.31% | Add +21.6% | 3,073,729 | $5.0M |
| Vanguard Group Inc. | 0.00% | Add +21.3% | 1,763,387 | $2.9M |
| Millennium Management | 0.00% | Add +1152.9% | 1,386,776 | $2.3M |
| Ieq Capital, LLC | 0.00% | Add +123.4% | 981,264 | $1.6M |
| ADAR1 Capital Management, LLC | 0.13% | Add +442.1% | 775,034 | $1.3M |
| Almitas Capital LLC | 0.18% | New | 494,778 | $806K |
| Renaissance Technologies | 0.00% | Add +23.4% | 468,598 | $764K |
| Geode Capital Management, LLC | 0.00% | Add +10.2% | 437,285 | $713K |
| BlackRock, Inc. | 0.00% | Add +2.9% | 345,461 | $563K |
| HighTower Advisors, LLC | 0.00% | No change | 308,500 | $503K |
| Union Square Park Capital Management, LLC | 0.26% | Add +86.0% | 224,746 | $366K |
| Marshall Wace, LLP | 0.00% | New | 210,045 | $342K |
| State Street Corp. | 0.00% | Add +58.6% | 198,111 | $323K |
| Alphabet Inc. | 0.01% | No change | 189,122 | $308K |
| Shay Capital LLC | 0.04% | Reduce -8.7% | 136,955 | $223K |
| Mariner, LLC | 0.00% | No change | 122,461 | $200K |
| Bridgeway Capital Management, LLC | 0.00% | Reduce -26.0% | 95,122 | $155K |
| Scharf Investments, LLC | 0.00% | No change | 91,061 | $148K |
| Simplex Trading, LLC | 0.00% | New | 88,519 | $144K |
| Gsa Capital Partners LLP | 0.01% | Add +157.9% | 87,235 | $142K |
| Northern Trust Corp. | 0.00% | Reduce -16.5% | 64,706 | $105K |
| Citadel Advisors | 0.00% | Reduce -39.4% | 56,914 | $93K |
| Jane Street Group, LLC | 0.00% | New | 35,160 | $57K |
| Operose Advisors LLC | 0.01% | New | 31,568 | $51K |
| Group One Trading LLC | 0.00% | New | 30,830 | $50K |
| Anfield Capital Management, LLC | 0.01% | No change | 30,227 | $49K |
| Cambridge Investment Research Advisors, Inc. | 0.00% | No change | 15,200 | $25K |
| Two Sigma Investments, LP | 0.00% | Reduce -13.3% | 15,080 | $25K |
| Nixon Peabody Trust Co. | 0.00% | No change | 11,126 | $18K |
| Wells Fargo & Company | 0.00% | No change | 6,990 | $11K |
| Advisory Services Network, LLC | 0.00% | New | 5,500 | $9K |
| Morgan Stanley | 0.00% | Reduce -14.2% | 3,690 | $6K |
| Bank of America Corp. | 0.00% | Reduce -28.1% | 2,089 | $3K |
| Tower Research Capital LLC (TRC) | 0.00% | New | 1,604 | $3K |
| UBS Group AG | 0.00% | Reduce -48.3% | 1,472 | $2K |
| Osaic Holdings, Inc. | 0.00% | Add +198.6% | 827 | $1K |
| JPMorgan Chase & Co. | 0.00% | No change | 469 | $764 |
| JDM Financial Group LLC | 0.00% | No change | 340 | $554 |
| Parallel Advisors, LLC | 0.00% | No change | 295 | $481 |
| Hurley Capital, LLC | 0.00% | No change | 121 | $197 |
| Harbour Investments, Inc. | 0.00% | No change | 100 | $163 |
| SBI Securities Co., Ltd. | 0.00% | Add +1.3% | 78 | $127 |
| Westside Investment Management, Inc. | 0.00% | No change | 75 | $122 |
| BNP Paribas Financial Markets | 0.00% | No change | 8 | $13 |
| Barclays PLC | 0.00% | Reduce -78.3% | 5 | $9 |
"% of holder's portfolio" is QUINCE THERAPEUTICS INC's weight in each manager's 13F, not the share of Quince Therapeutics Inc. the manager owns.